Effects of IgM-enriched immunoglobulin and fluid replacement on nerve conduction velocity in experimental sepsis

Ulusal Travma ve Acil Cerrahi Dergisi

Volumn 16, Issue 1, 2010, Pages 9-14

  Çankayali, Ilkin ^a   Doǧan, Yusuf Hakan ^a   Solak, Ilhami ^a   Eriş, Oǧuz ^a   Demirgören, Serdar ^a   Moral, Ali Reşat ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Experimental study; Fluid replacement; Immunoglobulin; Nerve conduction velocity; Sepsis

Indexed keywords

IMMUNOGLOBULIN M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; FLUID RESUSCITATION; MALE; NERVE CONDUCTION; NONHUMAN; RAT; SEPSIS; SUBSTITUTION THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; FLUID THERAPY; HYPOVOLEMIA; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MALE; NEURAL CONDUCTION; POLYNEUROPATHIES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 74549212179     PISSN: 1306696X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984;47:1223-31.
2. Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993;33:94-100.
3. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-16.
4. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140-63.
5. Tennilä A, Salmi T, Pettilä V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 2000;26:1360-3.
6. Cankayali I, Dogan YH, Solak I, Demirag K, Eris O, Demirgoren S, et al. Neuromuscular deterioration in the early stage of sepsis in rats. Crit Care 2007;11:R1.
7. Druschky A, Herkert M, Radespiel-Tröger M, Druschky K, Hund E, Becker CM, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001;27:686-93.
8. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997;23:1144-9.
9. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11.
10. Hughes RA, Raphaël JC, Swan AV, Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2004;(1):CD002063.
11. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
12. Van den Berg-Vos RM, Franssen H, Visser J, de Visser M, de Haan RJ, Wokke JH, et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol 2002;249:330-6.
13. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-9.
14. Pul R, Nguyen D, Schmitz U, Marx P, Stangel M. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuropharmacol 2002;25:254-9.
15. Otero-Antón E, González-Quintela A, López-Soto A, López-Ben S, Llovo J, Pérez LF. Cecal ligation and puncture as a model of sepsis in the rat: influence of the puncture size on mortality, bacteremia, endotoxemia and tumor necrosis factor alpha levels. Eur Surg Res 2001;33:77-9.
16. Ritter C, Andrades M, Frota Júnior ML, Bonatto F, Pinho RA, Polydoro M, et al. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Intensive Care Med 2003;29:1782-9.
17. Tredici G, Tredici S, Fabbrica D, Minoia C, Cavaletti G. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol 1998;36:31-40.
18. López-Rodríguez L, Hidalgo-Alquicira FG, Mimenza-Alvarado AJ. Neurological manifestations in critically ill patients. Rev Neurol 2006;43:155-67. [Abstract]
19. Zifko UA, Zipko HT, Bolton CF. Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci 1998;159:186-93.
20. Bolton CF. Evidence of neuromuscular dysfunction in the early stages of the systemic inflammatory response syndrome. Intensive Care Med 2000;26:1179-80.
21. Zochodne DW, Bolton CF, Laverty DA, Thompson RT, Driedger AA. The effects of sepsis muscle function; an electrophysiologic and P-31 NMR study. Electroencephalogr Clin Neurophysiol 1987;66:S115-S1165. (Bolton 2005 cross- over literature)
22. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2002;(1):CD001090.
23. Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996;104 Suppl 1:83-90.
24. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104 Suppl 1:3-9.
25. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991;126:236-40.
26. Pilz G, Kreuzer E, Kääb S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 1994;105:76-82.
27. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve 1994;17:1494-5.
28. Kawada J, Okada A, Saigan T, Sakai K, Hirose G. A case of critical illness polyneuropathy in association with peritonitis after sigmoid colon perforation. Rinsho Shinkeigaku 1995;35:509-12. [Abstract]
29. Op de Coul AA, Verheul GA, Leyten AC, Schellens RL, Teepen JL. Critical illness polyneuromyopathy after artificial respiration. Clin Neurol Neurosurg 1991;93:27-33.
30. Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol 2003;106:75-82.
31. Xuan D, Nicolau DP, Nightingale CH, Quintiliani R. Circulating tumor necrosis factor-alpha production during the progression of rat endotoxic sepsis. Chemotherapy 2001;47:194-202.
32. Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, et al. Treatment of gramnegative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 1991;19:1104-13.
33. Poynton CH, Jackson S, Fegan C, Barnes RA, Whittaker JA. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 1992;9:451-7.